FGP
ALT icon

Freestone Grove Partners’s Altimmune ALT Stock Holding History

Freestone Grove Partners’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,418
Closed -$104K – 579
2024
Q4 		$104K Buy
+14,418
New +$110K ﹤0.01% 561

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Freestone Grove Partners's ALT Position: Q1 2025 in Review

Freestone Grove Partners sold out of Altimmune (ALT) in Q1 2025, closing a stake of 14,418 shares — an estimated $104K sold.

Freestone Grove Partners first reported a position in ALT in Q4 2024 and held it in 1 quarter. The position peaked at $104K in Q4 2024. 176 funds tracked by Wall St. Rank hold ALT as of Q1 2025.

  • Freestone Grove Partners reported no remaining Altimmune position as of Q1 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 14,418 Altimmune shares in Q1 2025, an estimated $104K.
  • Freestone Grove Partners first reported a position in Altimmune in Q4 2024 and held it in 1 quarter.
  • Freestone Grove Partners's Altimmune position peaked at $104K in Q4 2024.
  • 176 funds tracked by Wall St. Rank held Altimmune as of Q1 2025.

Based on Freestone Grove Partners's 13F filing for Q1 2025, filed 15 May 2025.